Skip to main content

Day: February 27, 2024

Volaris Acquires Zeit AG

Provides time-tracking software to address complex strategic, operational, and regulatory requirements TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Volaris Group, a global leader in vertical market software, today proudly announced its acquisition of Zeit AG, a provider of workforce management solutions catering to the needs of complex European organizations. Zeit’s technology helps customers address time tracking for employees and projects, workforce and shift planning, and attendance management requirements. Commenting on the acquisition, Alice Luo, Chief Strategy Officer at Volaris Group said, “I look forward to working with Zeit AG to continue to deliver increasing value to their customers and supporting its mission to deliver new time tracking and workforce management innovation. Volaris best practices and learning opportunities...

Continue reading

Sotera Health Reports Fourth-Quarter and Full-Year 2023 Results; Provides 2024 Outlook

2023 net revenues increased 4.5% to $1.05 billion, compared to 2022 2023 net income of $51 million or $0.18 per diluted share 2023 Adjusted EBITDA(1) increased 4.3% to $528 million 2023 Adjusted EPS(1) decreased $0.15 to $0.81 per diluted share Full-year 2024 outlook of 4.0% – 6.0% growth for Net Revenues and Adjusted EBITDACLEVELAND, Feb. 27, 2024 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2023 and its initial 2024 outlook. For the fourth-quarter 2023, net revenues increased 23.3% to $310 million, compared with $252 million in the same period a year ago. Net...

Continue reading

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Pending further data and discussions with regulatory authorities, the expanded development plan for vepdegestrant will include a new Phase 3 trial in combination with CDK4/6 inhibitors in the second-line setting and a new Phase 3 trial of vepdegestrant plus Pfizer’s novel CDK4 inhibitor in the first-line setting – – Prioritized second-generation PROTAC® AR degrader ARV-766 after updated data showed robust efficacy in tumors with all AR LBD mutations in mCRPC – – Received regulatory clearance to initiate first-in-human Phase 1 clinical trials for PROTAC® targeting BCL6...

Continue reading

AGF Investments Launches Additional ETF Series

Offerings provide investors with access to alternatives, active fixed income, and U.S. small-mid cap equities in a mutual fund with ETF series option TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) announced that effective today it is expanding its line-up with the launch of ETF series options for AGF Global Real Assets Fund, AGF Total Return Bond Fund and AGF U.S. Small-Mid Cap Fund. “We continue to broaden our ETF offerings with the addition of ETF series options on long-running funds in key areas of focus for investors, including alternative assets and active fixed income,” said Meaghan Kelly, Chief Marketing & Product Officer, AGF Investments. “This launch builds on our commitment to provide options for our investors to access our capabilities in any of their preferred vehicles.”Fund...

Continue reading

Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it had a pre-investigational new drug application (PIND) meeting with the U.S. Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products (DCRP) on February 23, 2024 to discuss Arch’s plan to repurpose cilastatin as a new treatment to prevent toxin related acute kidney injury (AKI). Currently, there are no specific treatments for the prevention or treatment of AKI. Arch has the opportunity to sponsor a Phase II trial for cilastatin in toxin-related AKI targeting either nephrotoxic drug and/or rhabdomyolysis-associated AKI (explained further below). The PIND meeting provided the Arch team with guidance from the FDA for the content of a future IND application for...

Continue reading

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation for BEAM-302 in Alpha-1 Antitrypsin Deficiency on Track for First Half of 2024 Pending European Clinical Trial Application (CTA) Acceptance Ended Fourth Quarter 2023 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into 2027 CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported fourth quarter and full year 2023 financial results and reiterated anticipated milestones across the company’s sickle cell disease and genetic disease portfolios. “This...

Continue reading

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

– Reported OGSIVEO™ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application to the European Medicines Agency for nirogacestat for the treatment of desmoid tumors – – Presented positive topline data from Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN; on track to submit New Drug Application in first half of 2024 – – Submitted IND for SW-682 and received FDA clearance to proceed with Phase 1a trial – – Ended 2023 with $662.6 Million in Cash, Cash Equivalents and Marketable Securities – STAMFORD, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial...

Continue reading

Augmedix to Participate in Citizens JMP Technology Conference

SAN FRANCISCO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that members of its management team will participate in a fireside chat and host investor meetings at the Citizens JMP Technology Conference taking place in San Francisco on March 4, 2024. The fireside chat will be held at 11 a.m. PT / 2 p.m. ET. The webcast can be accessed live or as an archived replay on the Company’s Investor Relations website at https://ir.augmedix.com/. Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request on the conference website, contact your Citizens JMP representative, or email Augmedix’s IR team FNK IR at investors@augmedix.com. About...

Continue reading

Company Generates Record Subscriptions Sales for 2023 Holiday Season

Karaoke Subscription Service Generated $3.28 Million in Sales, 35% Increase Year-Over-Year Fort Lauderdale, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) — The Singing Machine Company, Inc. (“Singing Machine” or “the Company”) (NASDAQ: MICS) – the worldwide leader in consumer karaoke products, today announced a significant new milestone in its partnership with leading music, media and technology company, Stingray Group, Inc. (“Stingray”), for their shared karaoke subscription service. For 2023, the Stingray-Singing Machine subscription service generated a record $3.28 million in gross sales, representing a 34.8% increase over the prior calendar year subscription sales. As part of its agreement with Stingray, the Company’s profit share is calculated after deducting all costs of goods sold (COGS) and expenses associated with maintaining this...

Continue reading

Malibu Boats, Inc. to Participate at the Raymond James 2024 Institutional Investors Conference

LOUDON, Tenn., Feb. 27, 2024 (GLOBE NEWSWIRE) — Malibu Boats, Inc. (Nasdaq: MBUU) announced today that Jack Springer, Malibu’s Chief Executive Officer, will participate in a fireside chat at the Raymond James 2024 Institutional Investors Conference at the JW Marriott Grande Lakes in Orlando, Florida. The fireside chat is scheduled for 11:35 a.m. Eastern Time on Tuesday, March 5, 2024. An audio webcast of the presentation will be available by accessing the Malibu Boats Investor website at investors.malibuboats.com. A replay of the webcast will be available for 90 days following the event. About Malibu Boats, Inc. Based in Loudon, Tennessee, Malibu Boats, Inc. (MBUU) is a leading designer, manufacturer and marketer of a diverse range of recreational powerboats, including performance sport, sterndrive and outboard boats. Malibu Boats,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.